# Geographic Atrophy FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/geographic-atrophy

> 6 upcoming FDA catalysts in geographic Atrophy: tinlarebant (BLTE) on Jun to Sep 2027 (topline data readout); tinlarebant (BLTE) on June 2027 (primary completion); vonaprument (ANNX) on Jul to Oct 2027 (topline data readout); vonaprument (ANNX) on July 2027 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 23, 2026 | [JNJ-81201887 primary completion](https://sec-api.dev/pdufa/jnj-81201887) | JNJ | Geographic Atrophy | completed | "NCT05811351 (A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05811351)) |
| Jun to Sep 2027 | [Tinlarebant topline data readout](https://sec-api.dev/pdufa/tinlarebant) | BLTE | Geographic Atrophy | scheduled | "NCT05949593 (Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Belite Bio, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05949593)) |
| June 2027 | [Tinlarebant primary completion](https://sec-api.dev/pdufa/tinlarebant) | BLTE | Geographic Atrophy | scheduled | "NCT05949593 (Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Belite Bio, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05949593)) |
| Jul to Oct 2027 | [Vonaprument topline data readout](https://sec-api.dev/pdufa/vonaprument) | ANNX | Geographic Atrophy | scheduled | "NCT06510816 (A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor Annexon, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06510816)) |
| July 2027 | [Vonaprument primary completion](https://sec-api.dev/pdufa/vonaprument) | ANNX | Geographic Atrophy | scheduled | "NCT06510816 (A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor Annexon, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06510816)) |
| Jul to Oct 2029 | [Vonaprument topline data readout](https://sec-api.dev/pdufa/vonaprument) | ANNX | Geographic Atrophy | scheduled | "NCT07807969 (An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-07-31 (ESTIMATED); Lead Sponsor Annexon, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07807969)) |
| July 2029 | [Vonaprument primary completion](https://sec-api.dev/pdufa/vonaprument) | ANNX | Geographic Atrophy | scheduled | "NCT07807969 (An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-07-31 (ESTIMATED); Lead Sponsor Annexon, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07807969)) |

## Drugs

- [JNJ-81201887](https://sec-api.dev/pdufa/jnj-81201887) (JNJ)
- [Tinlarebant](https://sec-api.dev/pdufa/tinlarebant) (BLTE)
- [Vonaprument](https://sec-api.dev/pdufa/vonaprument) (ANNX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/geographic-atrophy.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Geographic Atrophy FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/geographic-atrophy

```bibtex
@misc{secapidev_indications_geographic_atrophy_20261116,
  title        = {Geographic Atrophy FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/geographic-atrophy}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_geographic_atrophy_20261116","title":"Geographic Atrophy FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/geographic-atrophy","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
